Verastem Oncology Inc. has entered into a discovery and development collaboration with Genfleet Therapeutics (Shanghai) Ltd. to advance three oncology discovery programs targeting RAS pathway-driven cancers.

Imunon Inc. has entered into a cooperative research and development agreement with the National Institute of Allergy and Infectious Diseases (NIAID) for the evaluation of the immunogenicity and efficacy of two Imunon DNA-based Lassa virus vaccine candidates. Under the 3-year agreement, the NIAID will assess the efficacy of Placcine DNA constructs against Lassa virus in guinea pig and non-human primate disease models, including both prime and prime-boost vaccine strategies.

Peptigrowth Inc. and Orizuru Therapeutics Inc. have entered into a joint development agreement to create a novel synthetic peptide that will replace a recombinant growth factor used in the manufacturing of a regenerative medicine product being developed by Orizuru.

Xnk Therapeutics AB has entered into a research collaboration with the Karolinska University Hospital to evaluate the suitability of the company's preclinical autologous natural killer (NK) cell therapy candidate XNK-02 as a novel therapy for treatment of acute myeloid leukemia (AML).

3Z ehf and Biotx.ai AG have established a strategic partnership to help advance the development of drugs for attention deficit hyperactivity disorder (ADHD).

Day One Biopharmaceuticals Inc. has entered into an exclusive, worldwide license agreement and research collaboration with Sprint Bioscience...

Chiesi Global Rare Diseases, a Chiesi Farmaceutici SpA business unit, has signed a co-development agreement with Aliada Therapeutics Inc.

Hebecell Corp. and Logomix Inc. have established a strategic partnership to research and develop gene-edited natural killer (NK) cells and discover genetic modifications that can create next-generation designer NK cells. Under the agreement, Logomix provides genome editing capabilities to Hebecell for development of next-generation designer Protonk cells.

Impact Biotech Ltd. has entered into an agreement with Maastricht University to collaborate on research focused on eye treatment to arrest the progression of pathological myopia, also known as myopic macular degeneration. The project will use Impact's padeliporfin vascular targeted photodynamic (VTP) therapy platform.

Celmatix Inc. and Aché Laboratórios Farmacéuticos SA will study the role of melatonin receptors and their agonists in polycystic ovary syndrome (PCOS). The two companies announced a collaboration, with a separate license and development agreement upon conclusion of the research.